"
Team:Freiburg/Project/1
From 2013.igem.org
m |
m |
||
| Line 51: | Line 51: | ||
<p class="first_order"><a href="https://2013.igem.org/Team:Freiburg/Project/modeling"> Modeling </a></p> | <p class="first_order"><a href="https://2013.igem.org/Team:Freiburg/Project/modeling"> Modeling </a></p> | ||
| + | <!-- | ||
<p id="sidebar_picture"> | <p id="sidebar_picture"> | ||
<img src="https://static.igem.org/mediawiki/2013/2/22/Project_freiburg_13_klein.png"> | <img src="https://static.igem.org/mediawiki/2013/2/22/Project_freiburg_13_klein.png"> | ||
<a href="https://2013.igem.org/Team:Freiburg/Project"><img src="https://static.igem.org/mediawiki/2013/d/dc/Project_freiburg_13_klein_yellow.png" style="margin-left:-190px;"> </a> | <a href="https://2013.igem.org/Team:Freiburg/Project"><img src="https://static.igem.org/mediawiki/2013/d/dc/Project_freiburg_13_klein_yellow.png" style="margin-left:-190px;"> </a> | ||
</p> | </p> | ||
| - | + | --> | |
</div> | </div> | ||
</div> | </div> | ||
Revision as of 12:16, 12 September 2013
Abstract
Just imagine there was a tool that combined all these aspects of lab work. A tool, that was able to rule several genes at once; a tool that allowed highly specific gene modulation via stimulus induction; a tool that would be a new approach to gene regulation.
This year’s Freiburg iGEM Team uses the prokaryotic CRISPR/Cas system to enable multiple endogenous gene regulation with minimal effort. The regulation is based on a protein-RNA-DNA interaction. Customizable RNAs function as a guide for our protein in order to target specific DNA sequences. By fusing effector domains to this protein, we aim at developing a tool for multiple and inducible gene activation and repression. Despite the system's prokaryotic origin, gene target sequences are adjustable for various organisms, offering a broad application variety of our tool. Due to its great potential, the CRISPR/Cas system has become of increasing importance in current research and can be implemented in a number of novel and interesting applications, such as gene therapy or tissue engineering.
Introduction
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
Aim
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
CONTENT
